- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
BDX
NYSE
Week ended 24 Jul 2026
Weekly Investor Report
Becton Dickinson and Company · Healthcare · Medical Instruments & Supplies
Latest close
156.4 USD
-1.1%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 0.3% above the Trend Line and sits at 52.2% of its 52-week range. The latest completed week returned -1.1%, after a 0.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 5d.
Setup score
42
out of 100
Latest Close
156.4 USD
24 Jul 2026
1W Return
-1.1%
latest completed week
4W Return
0.3%
short-term follow-through
12W Return
5.4%
quarterly tape
Trend Breadth
48.1%
25 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.1%
Latest completed week; four-week move 0.3%.
Indicator stack
26/63
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Bullish
42/100 conviction; expected move 9.8%.
News sentiment
57/100
40 relevant articles in the latest sentiment read.
Event risk
5d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 0.3% above the Trend Line and sits at 52.2% of its 52-week range. The latest completed week returned -1.1%, after a 0.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2012-week average 0.19
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.3% over four weeks, 5.4% over 12 weeks, and 10.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.16Latest activity-pressure read.
Pressure change123.7%Four-week change in activity pressure.
Leadership-4.89Latest relative-leadership reading.
RS change-15.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 97%
Model confidence 93%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength32/100Blend of value, momentum, and quality. Underlying universe rank 69; rank 1 is best.
Value29/100Relative valuation strength. Underlying universe rank 72; rank 1 is best.
Quality75/100Profitability and accounting quality. Underlying universe rank 26; rank 1 is best.
Momentum34/100Medium-term price momentum. Underlying universe rank 67; rank 1 is best.
Growth18/100Revenue and earnings growth. Underlying universe rank 83; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework32/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 37.9x Price divided by trailing earnings.
- Price / sales
- 2.0x Market value relative to trailing revenue.
- EV / EBITDA
- 12.7x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 7.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 46.5% Gross profit retained from each unit of revenue.
- Operating margin
- 10.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 21.8% Free cash flow generated from revenue.
- Return on invested capital
- 4.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 2.4% Latest one-year revenue growth.
- EPS growth
- -24.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 16.3% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 2.4% Cash dividends relative to market value.
- Buyback yield
- 5.8% Net share repurchases relative to market value.
- Shareholder yield
- 8.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBullish
BDX shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.27, expected move of 9.8%, and Sharemaestro trend signal inactive.
Conviction42/100
Expected move9.8%
Put/call volume0.27
Insider activity6 / 11
6 acquisitions and 11 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment57/100
Weighted news tone is neutral across 40 relevant articles.
15 positive · 24 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move9.8%Nearest-chain priced movement where available.
52-week drawdown-15.4%Distance below the 52-week high.
13-week volatility3.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher12 of 2613 weeks finished lower.
Best week+8.3%Week of 26 Jun.
Worst week-5.3%Week of 6 Mar.
Latest week-1.1%Week of 24 Jul.
Shape of recent returns
Strong gains4
Modest gains8
Flat weeks1
Modest losses9
Sharp losses4
Recent vol3.4%13-week weekly-return volatility.
Base vol3.5%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew3.2% / -2.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank44 / 100
Group average-1.3%
Trend breadth50.0%
Trend50.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Medical Instruments & Supplies
4-week rank19 / 50
Group average-2.7%
Trend breadth38.0%
Trend38.0%active weekly trend signals
MD74.0%positive activity pressure
RS26.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape40/100
Trend, activity pressure, participation, and risk combine to a 40/100 tape read.
Indicator analysis16/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.20; No reversal markers Factors42/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 10 SVQF32/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 692.5 of 1013 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options46/100BDX shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.27, expected move of 9.8%, and Sharemaestro trend signal inactive.
Bullish · Call-side pressure · Expected move 9.8% Sentiment57/100Weighted news tone is neutral across 40 relevant articles.
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold Insiders6 / 116 acquisitions and 11 disposals in the latest 180-day insider tape.
Earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 156.4 USD | -1.1% | 155.8 USD | 166.2 USD | 0.16 | -4.89 | 6.9M | Off |
| 17 Jul 2026 | 158.2 USD | 4.1% | 155.7 USD | 166.6 USD | 0.30 | -4.47 | 9.1M | Off |
| 10 Jul 2026 | 151.9 USD | -3.9% | 155.5 USD | 166.8 USD | -0.07 | -9.72 | 8.4M | Off |
| 3 Jul 2026 | 158.1 USD | 1.4% | 155.6 USD | 167.1 USD | -0.37 | -4.93 | 8.7M | Off |
| 26 Jun 2026 | 155.9 USD | 8.3% | 155.3 USD | 167.3 USD | -0.69 | -4.25 | 23.6M | Off |
| 19 Jun 2026 | 144.0 USD | -1.5% | 155.1 USD | 167.5 USD | -1.14 | -13.70 | 12.4M | Off |
| 12 Jun 2026 | 146.2 USD | -2.6% | 155.3 USD | 167.8 USD | -1.09 | -11.73 | 9.5M | Off |
| 5 Jun 2026 | 150.1 USD | 2.7% | 155.4 USD | 168.1 USD | -0.98 | -9.08 | 11.0M | Off |
| 29 May 2026 | 146.1 USD | -0.3% | 154.9 USD | 168.3 USD | -0.83 | -13.87 | 13.1M | Off |
| 22 May 2026 | 146.6 USD | 2.9% | 154.7 USD | 168.6 USD | -0.75 | -12.56 | 13.7M | Off |
| 15 May 2026 | 142.5 USD | -4.0% | 154.6 USD | 168.8 USD | -0.69 | -14.52 | 17.9M | Off |
| 8 May 2026 | 148.4 USD | 0.1% | 154.7 USD | 169.1 USD | -0.57 | -11.04 | 20.2M | Off |
| 1 May 2026 | 148.3 USD | -1.9% | 154.5 USD | 169.3 USD | -0.64 | -9.23 | 15.0M | Off |
| 24 Apr 2026 | 151.1 USD | -4.0% | 154.6 USD | 169.6 USD | -0.66 | -6.83 | 14.1M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.